These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28535112)

  • 21. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
    Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
    Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ibrutinib, an Approved Tyrosine Kinase Inhibitor as a Potential Cause of Recurrent Polymorphic Ventricular Tachycardia.
    Tomcsányi J; Nényei Z; Mátrai Z; Bózsik B
    JACC Clin Electrophysiol; 2016 Dec; 2(7):847-849. PubMed ID: 29759770
    [No Abstract]   [Full Text] [Related]  

  • 23. [Ibrutinib - new tool in hematologist hand, new challenges for internist].
    Majcherek M; Dworacka M; Dworacki G
    Wiad Lek; 2017; 70(1):92-95. PubMed ID: 28343201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
    Thorp BC; Badoux X
    Leuk Lymphoma; 2018 Feb; 59(2):311-320. PubMed ID: 28629235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Occult HBV reactivation induced by ibrutinib treatment: a case report.
    de Jésus Ngoma P; Kabamba B; Dahlqvist G; Sempoux C; Lanthier N; Shindano T; Van Den Neste E; Horsmans Y
    Acta Gastroenterol Belg; 2015 Dec; 78(4):424-6. PubMed ID: 26712054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece.
    Dimou M; Iliakis T; Pardalis V; Bitsani C; Vassilakopoulos TP; Angelopoulou M; Tsaftaridis P; Papaioannou P; Koudouna A; Kalyva S; Kyrtsonis MC; Panayiotidis P
    Leuk Lymphoma; 2019 Dec; 60(12):2939-2945. PubMed ID: 31184241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How I treat CLL patients with ibrutinib.
    Brown JR
    Blood; 2018 Jan; 131(4):379-386. PubMed ID: 29255067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.
    Kipps TJ; Fraser G; Coutre SE; Brown JR; Barrientos JC; Barr PM; Byrd JC; O'Brien SM; Dilhuydy MS; Hillmen P; Jaeger U; Moreno C; Cramer P; Stilgenbauer S; Chanan-Khan AA; Mahler M; Salman M; Eckert K; Solman IG; Balasubramanian S; Cheng M; Londhe A; Ninomoto J; Howes A; James DF; Hallek M
    Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):715-722.e6. PubMed ID: 31447270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA grants accelerated approval for ibrutinib for CLL.
    Dangi-Garimella S
    Am J Manag Care; 2014 Mar; 20(5 Spec No.):E10. PubMed ID: 25618623
    [No Abstract]   [Full Text] [Related]  

  • 30. Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins.
    Ambinder AJ; Hambley B; Shanbhag S; Merrill SA
    Am J Hematol; 2019 Nov; 94(11):E296-E299. PubMed ID: 31400009
    [No Abstract]   [Full Text] [Related]  

  • 31. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Chemoimmunotherapy should be standard frontline therapy.
    Wendtner CM
    Clin Adv Hematol Oncol; 2016 May; 14(5):336-8. PubMed ID: 27379694
    [No Abstract]   [Full Text] [Related]  

  • 32. Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia.
    Gordon MJ; Raess PW; Young K; Spurgeon SEF; Danilov AV
    Br J Haematol; 2017 Nov; 179(3):501-503. PubMed ID: 27391978
    [No Abstract]   [Full Text] [Related]  

  • 33. More About the Risk of Ibrutinib-associated Bleeding.
    Paolini A; Coluccio V; Luppi M; Marietta M
    Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):326-327. PubMed ID: 28161591
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
    Finnes HD; Chaffee KG; Call TG; Ding W; Kenderian SS; Bowen DA; Conte M; McCullough KB; Merten JA; Bartoo GT; Smith MD; Leis J; Chanan-Khan A; Schwager SM; Slager SL; Kay NE; Shanafelt TD; Parikh SA
    Leuk Lymphoma; 2017 Jun; 58(6):1376-1383. PubMed ID: 27820970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
    Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients.
    Molica S; Levato L; Mirabelli R; Tedeschi A; Lentini M
    Leuk Lymphoma; 2018 Nov; 59(11):2734-2736. PubMed ID: 29465275
    [No Abstract]   [Full Text] [Related]  

  • 37. Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies:
    Brown JR; Ghia P; Jurczak W; Kahl BS; Lamanna N; Robak T; Shadman M; Tam CS; Qiu L; Paik J; Salmi T; Wang L; Zhang J; Zhang M; Cohen A; Ma H; Tedeschi A
    Haematologica; 2024 Jul; 109(7):2277-2283. PubMed ID: 38426293
    [No Abstract]   [Full Text] [Related]  

  • 38. The clinical safety of ibrutinib in chronic lymphocytic leukemia.
    Molica S
    Expert Opin Drug Saf; 2015 Oct; 14(10):1621-9. PubMed ID: 26359217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival adjusting for crossover: phase 3 study of ibrutinib
    Coutre S; Tedeschi A; Robak T; Barr PM; Owen C; Bairey O; Burger J; Zhou C; Styles L; James DF; Kipps TJ
    Haematologica; 2018 Jun; 103(6):e249-e251. PubMed ID: 29170253
    [No Abstract]   [Full Text] [Related]  

  • 40. Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management.
    Iberri DJ; Kwong BY; Stevens LA; Coutre SE; Kim J; Sabile JM; Advani RH
    Br J Haematol; 2018 Jan; 180(1):164-166. PubMed ID: 27539794
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.